Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/531,506	YEN ET AL.	
Examiner	Art Unit	
Elli Peselev	1623	

	Elli Peselev	1623		
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress	
THE REPLY FILED 12 April 2010 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.				
 The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods: 	replies: (1) an amendment, affidavit eal (with appeal fee) in compliance v	, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request	
a) \boxtimes The period for reply expires <u>6</u> months from the mailing date	of the final rejection.			
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	dvisory Action, or (2) the date set forth in ter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	date of the final rejection	n.	
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of hortened statutory period for reply origin	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as	
2. The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the		
	out prior to the data of filing a brief	will not be entered be	001100	
3. The proposed amendment(s) filed after a final rejection, to (a) They raise new issues that would require further cor (b) They raise the issue of new matter (see NOTE below (c) They are not deemed to place the application in beta appeal; and/or	nsideration and/or search (see NOT w);	E below);		
(d) ☐ They present additional claims without canceling a continuation Sheet. (See 37 CFR 1.1.		cted claims.		
4. The amendments are not in compliance with 37 CFR 1.12	* **	mnliant Amendment (I	PTOL-324)	
 5. Applicant's reply has overcome the following rejection(s): 		Inpliant Amendment (1 1 OL-324).	
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 		imely filed amendmer	nt canceling the	
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proved The status of the claim(s) is (or will be) as follows: Claim(s) allowed: 11,46 and 54. Claim(s) objected to: 4 and 39. Claim(s) rejected: 1,12-14,18,31,44-46,52 and 60. Claim(s) withdrawn from consideration:		be entered and an ex	xplanation of	
AFFIDAVIT OR OTHER EVIDENCE				
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 				
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	l and/or appellant fail:	s to provide a	
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.	
11. The request for reconsideration has been considered but With respect to the rejection of claims 1, 12 and 13 as be compounds lack a hydroxy group at the 6-position. This column 5, lines 30-45 a compound that can have a hydro limited number of compounds a person having ordinary s the claimed compounds.	eing anticipated by Cassels et al, and argument has not been found pers boxy group at the 6-position and X3 i	oplicant conteds that t uasive since Cassels s H. or OH. From sai	the prior art et al disclose in d disclosure of a	
12. ☐ Note the attached Information <i>Disclosure Statement</i> (s). (13. ☐ Other:	PTO/SB/08) Paper No(s)			
				

Continuation Sheet (PTOL-303)

Application No.

/Elli Peselev/ Primary Examiner, Art Unit 1623

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

Advisory Action Before the Filing of an Appeal Brief

Part of Paper No. 20100420

Continuation of 3. NOTE: The terminology "R1 and R2 together may form a 5-7 heterocycle" and "R2 and R3 together may form a 5-7 membered heterocycle" is not disclosed in the specification, as originally filed. Note on page 6 of the specification it is stated "R1 and R2 together are heterocycles or R2 and R3 together are heterocycles"...